“We are delighted to have such an experienced manager and expert in the field of therapeutic proteins joining Direvo. Dr. von Rüden has an excellent reputation in the pharmaceutical/biotech and venture capital community”, comments Dr. Hubert Birner, Chairman of the Supervisory Board of Direvo and General Partner with TVM Capital.
“In my view, Direvo has the three prerequisites a company needs for sustainable growth: a good team, a top technology, and a solid financial basis. I am looking forward to the challenge and I thank the Supervisory Board and the team for the confidence shown in me”, says Dr. Thomas von Rüden, new CEO of Direvo.
Direvo Biotech AG Direvo Biotech AG generates and improves proteins and enzymes for pharmaceutical and industrial applications. For the fast and efficient optimization of proteins, Direvo is applying its proprietary screening-based Directed Evolution process. In addition, Direvo has developed a New Biological Entity (NBE®) platform, which enables the generation of novel proteases with tailor-made specificities and activities for nearly any pharmaceutical or industrial target protein. These NBE®-Proteases can be applied both in biocatalysis, food and feed, biorefineries and as drugs against cancer, inflammatory and other diseases. The company has signed collaboration agreements with Danisco, Novozymes, Evotec AG and other commercial and academic partners and has a broad product pipeline. Direvo is located in Cologne, Germany and operates with a constantly growing interdisciplinary team of 50 experts. For further information please visit http://www.direvo.com.
